异动解读|传奇生物盘中上涨5.25%,董事增持带动股价反弹

行情直击
Yesterday

11月18日,传奇生物盘中上涨5.25%,报16.98美元/股,成交额334.25万美元。

此次反弹有明确消息面催化:公司董事Peter Salovey最新披露买入20000股普通股,合计金额约18.33万美元,直接持股升至75096股。

此前公司三季度净利润5170万美元,同比扭亏为盈,CARVYKTI净销售额同比增长36%至约7.1亿美元,但财报后曾因多家机构下调评级与目标价而承压。董事增持在连续调整后释放一定信心信号,推动股价出现修复。

传奇生物科技有限公司是一家全球性的临床级生物制药公司,致力于肿瘤和其他适应症的新药的发现和开发。该公司的差异化技术、全球开发和制造战略及专业知识使其能够针对高未满足需求的适应症生成、测试和制造下一代细胞疗法。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10